Quercetin Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells
Frontiers in Bioscience-Landmark · 31.03.2026 · 31 (4)
DOI: 10.31083/fbl47715 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 31.03.2026. Verfasst von Jian Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, 410005 Changsha, Hunan, Chin…. Hauptthemen laut MEDLINE: Quercetin, Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Project of Hunan Provincial Health Commission.
Abstract (Originalsprache)
Background
Molecular targeted therapies play a crucial role in the management of hepatocellular carcinoma (HCC). Lenvatinib is a standard targeted agent for advanced HCC, while quercetin has emerged as a promising natural compound with anti-HCC potential. This study investigates the combined effect of quercetin and lenvatinib on HCC.
Methods
The human HCC cell line Huh7 and a nude mouse subcutaneous xenograft model were utilized. We evaluated cell proliferation, clonogenicity, invasion, migration, and apoptosis through Cell Counting Kit-8 (CCK-8), clonogenic, Transwell, and flow cytometry assays, respectively. Network pharmacology analysis was performed identify common targets. The protein expression levels of B-cell lymphoma 2 (Bcl-2), Bcl-2 associated X-protein (Bax), E-cadherin, N-cadherin, and protein tyrosine kinase 2 (PTK2) were assessed by Western blotting. In vivo experiments were conducted to validate the anti-tumor efficacy of the combination treatment.
Results
The combination of quercetin and lenvatinib significantly enhanced inhibition of Huh7 cell proliferation, colony formation, invasion, and migration (p < 0.01) and promoted apoptosis (p < 0.01) compared to individual treatments. Mechanistically, the combination treatment decreased the expression of Bcl-2 and N-cadherin while upregulating Bax and E-cadherin. PTK2 was identified as a key shared target, and the combination most effectively suppressed its protein expression. In vivo, the combination group demonstrated a higher tumor inhibition rate (p < 0.01) and a Combination Index (CDI) of 0.753.
Conclusion
Quercetin significantly enhances the anti-tumor efficacy of lenvatinib, likely through synergistic inhibition of PTK2 expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, The Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, 410005 Changsha, Hunan, China.
- Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital/The First Affiliated Hospital of Hunan Normal University, 410005 Changsha, Hunan, China.
Förderung
- Research Project of Hunan Provincial Health Commission
Zitieren
APA
Li, J., Yin, Q., Liu, K., Chen, X., & Zhou, Y. (2026). Quercetin Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells. Frontiers in Bioscience-Landmark, 31(4). https://doi.org/10.31083/fbl47715
Vancouver
Li J, Yin Q, Liu K, Chen X, Zhou Y. Quercetin Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells. Frontiers in Bioscience-Landmark. 2026;31(4). doi:10.31083/fbl47715
BibTeX
@article{Li2026,
author = {Li, Jian and Yin, Qinghua and Liu, Kai and Chen, Xu and Zhou, Yang},
title = {Quercetin Enhances the Antitumor Effect of Lenvatinib on Hepatocellular Carcinoma Cells},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {4},
doi = {10.31083/fbl47715}
}
EUVIMED